We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arbutus Biopharma (ABUS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arbutus Biopharma is one of 1051 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 0.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ABUS has returned 11.2% so far this year. At the same time, Medical stocks have gained an average of 1.5%. This means that Arbutus Biopharma is outperforming the sector as a whole this year.
Another stock in the Medical sector, Entera Bio Ltd. (ENTX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 235%.
Over the past three months, Entera Bio Ltd.'s consensus EPS estimate for the current year has increased 66.7%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, a group that includes 506 individual stocks and currently sits at #79 in the Zacks Industry Rank. Stocks in this group have lost about 7.9% so far this year, so ABUS is performing better this group in terms of year-to-date returns. Entera Bio Ltd. is also part of the same industry.
Arbutus Biopharma and Entera Bio Ltd. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arbutus Biopharma (ABUS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Arbutus Biopharma is one of 1051 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 0.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ABUS has returned 11.2% so far this year. At the same time, Medical stocks have gained an average of 1.5%. This means that Arbutus Biopharma is outperforming the sector as a whole this year.
Another stock in the Medical sector, Entera Bio Ltd. (ENTX - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 235%.
Over the past three months, Entera Bio Ltd.'s consensus EPS estimate for the current year has increased 66.7%. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry, a group that includes 506 individual stocks and currently sits at #79 in the Zacks Industry Rank. Stocks in this group have lost about 7.9% so far this year, so ABUS is performing better this group in terms of year-to-date returns. Entera Bio Ltd. is also part of the same industry.
Arbutus Biopharma and Entera Bio Ltd. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.